Paper Details

  1. Home
  2. Paper Details

Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.

Author: FurutaTakahisa, HamayaYasushi, IwaizumiMoriya, KagamiTakuma, MiyajimaHiroaki, OsawaSatoshi, SugimotoKen, SuzukiTakahiro, UmemuraKazuo, UotaniTakahiro, YamadeMihoko

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Vonoprazan, a new acid suppressant, was found to more potently attenuate the antiplatelet function of clopidogrel than esomeprazole in healthy volunteers. Esomeprazole did not affect the antiplatelet function of prasugrel regardless of CYP2C19 genotype.
Paper Details　
Original Abstract of the Article :
Drug-drug interaction between antiacid and antiplatelet agents has not been fully elucidated. Vonoprazan, a new potassium competitive acid blocker, has been available in Japan. CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole, and vonoprazan. Using a P2Y12 as...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cpt.863

データ提供：米国国立医学図書館（NLM）

Vonoprazan and Esomeprazole: Impact on Antiplatelet Function

This study explores the complex world of pharmacology, investigating the potential drug-drug interactions between antiacid medications and antiplatelet agents. The researchers are trying to understand how two proton pump inhibitors, vonoprazan and esomeprazole, affect the antiplatelet function of clopidogrel and prasugrel. They conducted a study with 31 healthy volunteers, analyzing the impact of these medications on platelet aggregation based on the CYP2C19 genotype.

Vonoprazan's Greater Impact on Antiplatelet Function

The study found that vonoprazan, a new potassium competitive acid blocker, decreased the antiplatelet function of both clopidogrel and prasugrel more potently than esomeprazole. This suggests that vonoprazan may have a greater impact on platelet function and potentially increase the risk of bleeding when used concurrently with antiplatelet agents.

Dr. Camel's Conclusion

This study highlights the importance of carefully considering potential drug-drug interactions when prescribing medications, particularly for patients taking antiplatelet agents. It underscores the need for ongoing research to better understand the impact of various medications on platelet function and optimize patient safety.
Date :
  1. Date Completed 2019-05-20
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

28875498

DOI: Digital Object Identifier

10.1002/cpt.863

Related Literature

Article Analysis
・Effects of vonoprazan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.